JPMorgan Reinstates Alnylam Pharmaceuticals (ALNY) at Overweight
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $228.61 +1.79%
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Join SI Premium – FREE
JPMorgan analyst Jessica Fye reinstates coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY) with a Overweight rating and a price target of $420.00.
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $294.30 yesterday.
You May Also Be Interested In
- BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
- BMO Capital Starts Ascendis Pharma (ASND) at Outperform
- Noble Capital Starts Xerox (XRX) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
